Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myelomaRecommendation based on IMROZ ...

The drugmaker has won an appeal against NICE's recent final draft guidance on Sarclisa (isatuximab) as a regimen alongside ...

The FDA has approved Sarclisa (isatuximab) as a first-line therapy for blood cancer multiple myeloma as a combination regimen alongside bortezomib, lenalidomide, and dexamethasone (VRd), for ...

Sanofi (NASDAQ:SNY) said on Thursday its multiple myeloma drug Sarclisa (isatuximab) met the primary endpoints of a late-stage trial. The drug is currently indicated for use in a combination ...

Sanofi SNY announced that the FDA has approved the label expansion for the use of its multiple myeloma (MM) drug, Sarclisa (isatuximab). With this nod, Sarclisa is now approved in combination with ...

Adding isatuximab, an anti-CD38 monoclonal antibody, to bortezomib, lenalidomide, and dexamethasone (VRd) may improve outcomes in transplant-ineligible patients with multiple myeloma. New research ...

Samer A. Al'Hadidi, MD, MS, discusses the response and survival of 2 quadruplet therapy trials for patients with ...

In September, commenced patient dosing to investigate evorpacept plus SARCLISA® (isatuximab-irfc) and dexamethasone in ...

After a positive phase 3 trial, Johnson & Johnson hopes its Darzalex could become the first treatment option for patients with smoldering multiple myeloma, an early-stage form of the blood disorder.

Non-secretory myeloma is a rare form of myeloma. In people with this form, myeloma cells do not release an abnormal protein called paraprotein, making it harder to diagnose than other types of ...

In September, commenced patient dosing to investigate evorpacept plus SARCLISA® (isatuximab-irfc) and dexamethasone in patients with relapsed or refractory multiple myeloma (RRMM) in the Sanofi ...